Introduction
============

Femoral artery access remains the most commonly used arterial access during coronary angiography and intervention despite an increase in radial procedures.[@b1-tcrm-13-401],[@b2-tcrm-13-401] Femoral access complications remain infrequent, ranging from \<1% to 17% of procedures.[@b3-tcrm-13-401]--[@b7-tcrm-13-401] It is not uncommon to see patients presenting to the cardiac catheterization laboratory on oral anticoagulant (OAC) fully or partially anticoagulated and undergoing common femoral artery (CFA) access.[@b8-tcrm-13-401] Several new OAC (NOACs; oral Xa and thrombin inhibitors) have emerged within the past 3--6 years and are now an alternative to warfarin in treating patients with nonvalvular atrial fibrillation or venous thromboembolic disease.[@b9-tcrm-13-401] Some data suggest that coronary procedures can be performed safely with uninterrupted OAC at the time of the index procedure.[@b10-tcrm-13-401]

In this study, we investigated whether orally anticoagulated patients have a higher risk of femoral access site complications when compared to patients who are not anti-coagulated with OAC during coronary procedures.

Methods
=======

We retrospectively reviewed data from 779 consecutive patients who underwent a cardiac procedure (diagnostic or interventional) at a tertiary medical center. Patients were identified from the cardiac catheterization procedural log. Medical records were reviewed by dedicated research assistants, and data entry was audited by a Clinical Research Associate. The study was approved by the Genesis Health System Institutional Review Board at the medical center. Informed consent by patients to review their medical records was waived by the same institutional review board due to the retrospective nature of the study and the large number of patients included that made it impractical or impossible to obtain informed consent from patients. All investigators signed a patient confidentiality agreement with the medical center.

Patients were considered (group A) fully or partially anticoagulated if they had an international normalized ratio (INR) ≥1.6 on the day of the procedure or were on warfarin or NOAC within 48 h and 24 h of the procedure, respectively. The nonanticoagulated group (group B) had an INR \<1.6 or have stopped their warfarin and NOAC \>48 h and \>24 h preprocedure, respectively. Non-CFA and bilateral CFA accesses were excluded. Radial procedures were excluded as they are performed infrequently in our medical center.

The index primary end point of the study was defined as the composite end point of major bleeding, vascular complications (arteriovenous (AV) fistula or pseudoaneurysm), or cardiovascular death during index hospitalization. The 30-day primary end point was defined as the occurrence of the index primary end point and up to 30 days postprocedure. Other secondary end points included the following major adverse events: major bleeding, total death, cardiac death, vascular complications, including AV fistula and pseudoaneurysm, stroke (hemorrhagic or embolic), and myocardial infarction. Demographic, clinical, and procedural angiographic variables were collected ([Table 1](#t1-tcrm-13-401){ref-type="table"}).

Major bleeding was defined as a drop of 3 units of hemoglobin or transfusion of 2 units of blood with a clear source of bleed: intracranial bleed or retroperitoneal bleed. Myocardial infarction was defined as the presence of 2 of the following: rise in troponin and presence of chest pain or ST segment elevation. Clinically relevant nonmajor bleed was defined as the occurrence of a bleed that required an intervention (stopping the OAC or extending hospital stay or admission) without meeting the definition of a major bleed.

Statistical analysis
--------------------

Descriptive analysis of all variables was performed using mean ± standard deviation for continuous variables and percentages for dichotomous variables. Independent samples *t*-test was used for continuous variables and Fisher's exact testing for dichotomous variables. Bivariate analysis was used to compare Group A (anticoagulated) and Group B (not anticoagulated) and the unadjusted differences between subjects who met the 30-day primary composite endpoint versus subject who did not. Binary logistic regression analysis with backward elimination was performed with modeling for gender, low body weight (\<60 kg), preprocedural hemoglobin, creatinine clearance (CrCl), activated clotting time, fluoroscopy time, body mass index (BMI), heparin dose/weight (kg), prolonged procedure time (\>90 min), urgency of procedure, group A (vs B), heparin, and bivalirudin. Collinearity existed between prolonged procedure time and fluoroscopy time; prolonged procedure time was selected for modeling. CrCl, activated clotting time, and BMI were transformed using Johnson transformation due to nonnormality. Interactions between variables were explored with no significance. Hosmer--Lemeshow goodness of fit test was used for model determination (*P*-value \>0.05). Minitab 17 and Cytel Studio 11 were used to conduct the analysis.

Results
=======

Demographic and clinical characteristics
----------------------------------------

A total of 779 patients were included in this study (mean age 65.6±12.2 years, males 62.4%). Of these patients, 27 (3.5%) patients were in group A. [Table 1](#t1-tcrm-13-401){ref-type="table"} describes patients' demographic and clinical characteristics. Notably, 464/779 (59.6%) underwent an interventional procedure and received intraprocedural anticoagulation with either bivalirudin (21.2%) or heparin (35.0%) or both (2.4%). GpIIb/IIIa inhibitors were rarely used (0.9%). Closure devices were used in most patients (98.0%), predominantly Perclose (69.0%) followed by Angioseal (27.3%).

Outcomes
--------

The index primary end point was met in 11/779 (1.4%) patients. All adverse events at index procedure were seen in 25/779 (3.2%) patients. These were adjudicated to be definitely or maybe related to access site in 7/25 (28.0%) and procedure related in 12/25 (48.0%). There was no difference in the primary composite end point at index between group A (1/27 \[3.7%\]) and group B (10/752 \[1.3%\]; *P*=0.3155). There was also no difference in the total adverse events at index between group A (3/27 \[3.7%\]) and group B (22/752 \[2.9%\]; *P*=0.6391).

The 30-day primary composite end point ([Table 2](#t2-tcrm-13-401){ref-type="table"}) was met in 18/779 (2.3%) patients. All adverse events at the 30-day postprocedure were seen in 43/779 (5.5%) patients. These were adjudicated to be definitely or maybe related to access site in 7/42 (17.9%) and procedure related in 14/42 (48.3%). There was no difference in the 30-day primary composite end point between group A (2/27 \[7.4%\]) and group B (16/752 \[2.1%\]; *P*=0.1313). There was also no difference in the total adverse events at 30 days between group A (4/27 \[14.8%\]) and group B (39/752 \[5.2%\]; *P*=1.000).

In bivariate analysis ([Table 3](#t3-tcrm-13-401){ref-type="table"}), the 30-day primary end point was significantly associated with female gender (*P*=0.0481), weight \<60 kg (*P*=0.0040), low hemoglobin at baseline (*P*=0.0410), reduced CrCl (*P*=0.0001), high activated clotting time (ACT) (*P*=0.0150), high intraprocedural heparin dose (units per kg; *P*=0.0110), and high BMI (*P*=0.0040) but not group A versus group B. There was also no association between the type of coronary procedure done (cardiac catheterization vs intervention) and the primary adverse event at the time of the procedure (0.95% and 1.72%, respectively, *P*=0.5393) or at 1 month (*P*=1.000). However, patients who underwent an intervention in group B had a higher primary adverse event at 1 month when compared to cardiac catheterization patients in group B.

Multivariable analysis ([Table 4](#t4-tcrm-13-401){ref-type="table"}) using various models showed that a low CrCl (odds ratio \[OR\] 0.56, *P*=0.0200) and underweight patients (\<60 kg; OR 3.94, *P*=0.0300) were independent predictors of the 30-day primary composite end point but not oral anticoagulation (*P*=0.15). On the other hand, a low hemoglobin preprocedure (OR 0.65, *P*=0.0140), emergent/urgent procedure (OR 8.9, *P*\<0.0000), a prolonged procedure time (OR 12.08, *P*=0.0010), and orally anticoagulated patients (OR 3.82, *P*=0.0500) were independent predictors of the 30-day composite primary and secondary end points.

Discussion
==========

Adverse events during index coronary angiography occurred in 3.7% of patients. This is within the reported range of access site complications. In multivariate analysis, irrespective of the intraprocedural anticoagulant, patients with uninterrupted anticoagulation with OAC did not have an increase in the composite primary end point of major bleeding, vascular complications (AV fistula or pseudoaneurysm), or cardiovascular death during their index hospitalization and up to 30 days when compared to patients who were not anticoagulated with OAC.

These data, however, do not apply to patients who receive lytic therapy (as none of our patients had received a thrombolytic) or GPIIb/IIIa inhibitors (\<1% of patients in our cohort).[@b11-tcrm-13-401] Furthermore, these data are in the setting of the majority of patients receiving a closure device and, therefore, cannot be extended to those who undergo hemostasis with manual compression. There are conflicting data on the value of vascular closure devices in reducing complications postfemoral arterial access in patients undergoing cardiac procedures.[@b12-tcrm-13-401]--[@b15-tcrm-13-401] Recent data, however, seem to favor closure devices in reducing complications postcardiac diagnostic or interventional procedures.[@b14-tcrm-13-401],[@b15-tcrm-13-401] Finally, no radial approach patients were included in this study (limited use of radial in our laboratory). Recent studies have shown that both radial and femoral approaches were safe after percutaneous coronary intervention but a radial approach had less vascular complications.[@b2-tcrm-13-401],[@b16-tcrm-13-401] On the other hand, a femoral approach with vascular closure device (Angioseal) was noninferior to a radial approach in reducing postcardiac procedure complications.[@b17-tcrm-13-401] However, studies have shown that patients with uninterrupted warfarin undergoing radial approach had less vascular complications.[@b18-tcrm-13-401],[@b19-tcrm-13-401]

In this study, univariate analysis indicated that the higher the units per kilogram of unfractionated heparin administered intraprocedurally, the higher the primary composite adverse end points. Intraprocedural antithrombotic therapy has been shown to increase the risk of vascular complications in patients who are on warfarin irrespective of the degree of anticoagulation.[@b20-tcrm-13-401] Multivariate analysis, however, showed that intraprocedural heparin, when adjusted for CrCl and underweight patients (\<60 kg), did not predict adverse events. The presence of renal failure is a strong predictor of adverse events postcardiac intervention.[@b21-tcrm-13-401],[@b22-tcrm-13-401] In a study of 8,521 patients evaluating the relationship between glomerular filtration rate (GFR) and all-cause mortality, there was a decline in survival postcatheterization that correlated with a decline in GFR. In this study, for every 10-unit decrease in GFR, there was \~17.2% relative increase in mortality risk. This is consistent with the findings in this study that showed that an increase in CrCl reduces the likelihood of occurrence of the 30-day composite end points of major bleeding, vascular complications, and cardiovascular death (OR 0.56). Also, several studies have shown that a high or low BMI correlate with vascular complications.[@b3-tcrm-13-401]--[@b5-tcrm-13-401],[@b7-tcrm-13-401] In our study, a low weight of \<60 kg was an independent predictor of complications in orally anticoagulated patients.

A lower preprocedural hemoglobin, OAC, a longer procedure time, and an urgent/emergent procedure independently predicted the combined 30-day adverse events (major bleeding, cardiac and noncardiac death, stroke, myocardial infarction, and vascular complications). These events are driven by death, myocardial infarction, and stroke and likely reflect a high-risk patient population with more unstable symptoms and requiring prolonged procedures.[@b23-tcrm-13-401],[@b24-tcrm-13-401]

Limitation of the study
=======================

This is a retrospective study and therefore selection bias cannot be ruled out. This, however, was addressed by including all consecutive patients with the exception of excluding those with bilateral CFA and non-CFA access sites (small number of patients in our center). Therefore, data in this study do not apply to radial procedures. Radial access appears to be safe in patients actively on anticoagulation and is now becoming more widely adopted in the US. Finally, this study needs to be verified in a larger registry of patients on anticoagulation as the overall number of anticoagulated patients in this study is relatively small and with low number of patients reaching end points.

Conclusion
==========

Independent predictors of the combined end points of major bleeding, vascular complications, or cardiovascular death at index or up to 30 days in patients undergoing coronary procedures are low weight (\<60 kg) and renal insufficiency but not OAC. These conclusions are limited to patients undergoing femoral vascular access and not receiving GPIIb/IIIa inhibitors or lytic therapy.
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###### 

Descriptive analysis

  Baseline variables                                   n     Mean ± SD
  ---------------------------------------------------- ----- -------------
  Age (years)                                          779   65.6±12.2
  Body mass index (kg/m^2^)                                  
   Male                                                486   31.2±6.5
   Female                                              293   31.3±7.7
  Creatinine clearance (mL/min)                              
   Male                                                486   105.1±48.7
   Female                                              293   82.8±42.6
  International normalized ratio                       51    1.7±1.2
  Activated clotting times (s)                         193   259.8±65.7
  Procedure time (min)                                 778   52.1±49.7
  Fluoroscopy time (min)                               776   15.2±17.9
  Contrast used (mL)                                   777   180.4±111.5
  Systolic blood pressure when sheath removed (mmHg)   767   130.5±22.3
  Intraprocedural heparin (units per kg)               296   94.1±47

                                                                    n     n′    \%
  ----------------------------------------------------------------- ----- ----- ------
  Male                                                              779   486   62.4
  Age \>75 (years)                                                  779   184   23.6
  Weight \<60 kg                                                    779   50    6.4
  Hyperlipidemia                                                    779   590   75.7
  Hypertension                                                      779   593   76.1
  Diabetes mellitus                                                 779   282   36.2
  History of smoking                                                779   445   57.1
  History of heart failure                                          779   68    8.7
  History of atrial fibrillation                                    779   83    10.7
  History of myocardial infarction                                  779   145   18.6
  Systolic blood pressure (\>140/90 mmHg) after sheath is removed   779   85    10.9
  Sheath size                                                       802         
   6 French                                                               428   53.4
   8 French                                                               363   45.3
   Others                                                                 11    1.3
  Method of hemostasis                                              802         
   Closure device                                                         567   70.7
   Closure device and manual hemostasis                                   219   27.3
   Manual hemostasis                                                      12    1.5
   Others                                                                 4     0.5
  Type of closure device                                            802         
   Perclose                                                               557   69.4
   Angioseal                                                              221   27.6
   Others                                                                 13    2.3
   Not applicable                                                         11    1.6
  Antiplatelet therapy during procedure                             779         
   None                                                                   19    2.4
   Mono antiplatelet                                                      202   25.9
   Dual antiplatelet                                                      554   71.1
   Others                                                                 4     0.5
  Oral anticoagulation during procedure                             779         
   Anticoagulated (group A)                                               27    3.5
   Not anticoagulated (group B)                                           752   96.5
  Intraprocedural parenteral anticoagulation                        779         
   None                                                                   315   40.4
   Bivalirudin                                                            165   21.2
   Heparin                                                                273   35.0
   Heparin and bivalirudin                                                19    2.4
   GpIIb/IIIa inhibitors and heparin                                      6     0.8
   GpIIb/IIIa inhibitors and heparin and bivalirudin                779   1     0.1
  Procedure urgency                                                 779         
  Elective                                                                479   61.5
  Urgent                                                                  233   29.9
  Emergent                                                                67    8.6
  Prolonged procedure time (\>90 min)                               779   98    12.6
  Low hemoglobin \<10 g per dL preprocedure                         779   27    3.5

**Abbreviation:** SD, standard deviation.

###### 

Adverse events in orally anticoagulated (group A) versus nonanticoagulated (group B) patients

  Adverse events                                                                                             Group A     Group B     Total           *P*-value
  ---------------------------------------------------------------------------------------------------------- ----------- ----------- --------------- -----------
  Index adverse events                                                                                       n=27        n=752       n=779           
   Major bleeding                                                                                            1           7           8               
   Clinically relevant nonmajor bleed                                                                        0           3           3               
   Noncardiovascular death                                                                                   0           3           3               
   Cardiac death                                                                                             2           6           8               
   Vascular complications                                                                                    0           3           3               
   Total adverse events, n (%)                                                                               3 (11.1%)   22 (2.9%)   25 (3.2%)       0.7500
    Adverse events maybe or definitely related to access site                                                                        7/25 (28%)      
    Adverse events maybe or definitely related to procedure                                                                          12/25 (48%)     
   Primary composite endpoint at index, (major bleeding, vascular complications, and cardiac death), n (%)   1 (3.7%)    10 (1.3%)   11 (1.4%)       0.3200
  30-day adverse events                                                                                      n=27        n=752       n=779           
   Major bleeding                                                                                            2           10          12              
   Clinically relevant nonmajor bleed                                                                        0           3           3               
   Noncardiovascular death                                                                                   0           3           3               
   Cardiac death                                                                                             2           7           9               
   Stroke                                                                                                    0           3           3               
   Myocardial infarction                                                                                     0           7           7               
   Vascular complications                                                                                    0           6           6               
   Total adverse events, n (%)                                                                               4 (14.8%)   39 (5.2%)   43 (5.5%)       0.6300
    Adverse events maybe or definitely related to access site                                                                        9/43 (20.9%)    
    Adverse events maybe or definitely related to procedure                                                                          15/43 (34.9%)   
   30-day primary composite end point, (major bleeding, vascular complications, and cardiac death), n (%)    2 (7.4%)    16 (2.1%)   18 (2.3%)       0.1300

###### 

Unadjusted differences between subjects who met the 30-day primary composite endpoint versus subjects who did not

  Variables                           Total   No end point met   30-day primary end point met   *P*-value
  ----------------------------------- ------- ------------------ ------------------------------ -----------
  Gender                              n=779                                                     
   Female                             293     282 (36.5%)        11 (61.1%)                     0.0481
   Male                               486     479 (61.5%)        7 (38.9%)                      
  Weight                              n=779                                                     
   \<60 kg                            729     716 (91.9%)        13 (72.2%)                     0.0040
   ≥60 kg                             50      45 (5.8%)          5 (27.8%)                      
  Access site-related complications   n=43                                                      
   Unrelated                          34      24 (92.3%)         10 (58.8%)                     0.0115
   Maybe and definite                 9       2 (7.7%)           7 (41.2%)                      
  Procedure-related complications     n=42                                                      
   Unrelated                          26      20 (83.3%)         6 (33.3%)                      0.0014
   Maybe and definite                 16      4 (16.7%)          12 (66.7%)                     
  Coronary procedure                  n=779                                                     
   Cardiac catheterization            315     309 (40.6%)        6 (33.3%)                      0.6318
   Cardiac intervention               464     452 (59.4%)        12 (66.7%)                     
  Preprocedure hemoglobin (g/dL)      747     729                18                             0.0410
  Creatinine clearance (mL/min)       771     753                18                             0.0001
  Activated clotting time (s)         193     185                8                              0.0150
  Fluoroscopy time (min)              776     758                18                             0.0230
  Body mass index (kg/m^2^)           779     761                18                             0.0040
  Heparin/weight (units per kg)       296     285                11                             0.0110

###### 

Logistic regression analysis for predictors of adverse events

  Variables                                                                  Odds ratio (OR)   95% OR confidence interval   *P*-value
  -------------------------------------------------------------------------- ----------------- ---------------------------- -----------
  Analysis for predictors of 30-day primary composite end point                                                             
   Transformed creatinine clearance                                          0.56              0.33, 0.92                   0.0200
   Weight \<60 (vs \>60) kg                                                  3.94              1.26, 12.37                  0.0300
   Group A (vs B)                                                            2.12              0.80, 17.93                  0.1500
  Analysis for predictors of 30-day composite primary and secondary events                                                  
   Transformed hemoglobin preprocedure                                       0.65              0.46, 0.92                   0.0140
   Group A (vs B)                                                            3.82              1.15, 12.68                  0.0500
   Urgency of procedure (emergent/urgent vs elective)                        8.9               3.61, 21.91                  \<0.0000
   Procedure time                                                            12.08             3.29, 44.30                  0.0010
